Orchid lands Russian partner for Exblifep; $178M over 10 years

Orchid Pharma signed a licensing and supply agreement with Russia's Pharmasyntez JSC to commercialize its novel antibiotic Exblifep in the country. The deal covers exclusive rights for complicated urinary tract infections and hospital-acquired pneumonia. Revenue, though, is years away — it's contingent on Russian health ministry approval and market uptake. Still, this is the first concrete out-licensing deal for Exblifep, following earlier telegraphed discussions and a revised lifetime sales target of $2 billion. Orchid estimates the partnership could generate $178 million over the first decade from hospital procurement. That's a material opportunity for a mid-cap pharma with a market cap of ₹4,886 crore. The US and EU approvals are already in hand. The real bet: whether Pharmasyntez can navigate Russian regulatory and geopolitical hurdles to turn that $178 million into actual revenue. It won't be quick.